Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  • Paiva, B.
  • Puig, N.
  • Cedena, M.T.
  • Rosiñol, L.
  • Cordón, L.
  • Vidriales, M.B.
  • Burgos, L.
  • Flores-Montero, J.
  • Sanoja-Flores, L.
  • Lopez-Anglada, L.
  • Maldonado, R.
  • de la Cruz, J.
  • Gutierrez, N.C.
  • Calasanz, M.J.
  • Martin-Ramos, M.L.
  • Garcia-Sanz, R.
  • Martinez-Lopez, J.
  • Oriol, A.
  • Blanchard, M.J.
  • Rios, R.
  • Martin, J.
  • Martinez-Martinez, R.
  • Sureda, A.
  • Hernandez, M.T.
  • de la Rubia, J.
  • Krsnik, I.
  • Moraleda, J.M.
  • Palomera, L.
  • Bargay, J.
  • Van Dongen, J.J.M.
  • Orfao, A.
  • Mateos, M.V.
  • Blade, J.
  • San-Miguel, J.F.
  • Lahuerta, J.J.
PURPOSE: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1, 100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. RESULTS: Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P < .001) and an 88% reduction in the risk of death (hazard ratio, 0.12; 95% CI, 0.05 to 0.29; P < .001). Timing of undetectable MRD (after induction v intensification) had no impact on patient survival. Attaining undetectable MRD overcame poor prognostic features at diagnosis, including high-risk cytogenetics. By contrast, patients with Revised International Staging System III status and positive MRD had dismal progression-free and overall survivals (median, 14 and 17 months, respectively). Maintenance increased the rate of undetectable MRD by 17%. CONCLUSION: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

  • Medina, Alejandro
  • Jimenez, Cristina
  • Sarasquete, Maria Eugenia
  • González, Marcos
  • Chillón, M. Carmen
  • Balanzategui, Ana
  • Gironella Mesa, Mercedes
Investigació genètica; Mieloma, Investigación genética; Mieloma, Genetics research; Myeloma, Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program. The authors wish to thank José Pérez, Alicia Antón, Montserrat Hernández-Ruano, Estrella Arnés, Rebeca Maldonado, Mercedes Jiménez, Alejandra Martín, Isabel Sánchez, Rocío Corral and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, as well as the Spanish Multiple Myeloma “GEM-PETHEMA” group for providing clinical data. The authors are also very grateful to the patients who participated in this study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

  • Medina, Alejandro|||0000-0001-5609-2969
  • Jiménez, Cristina
  • Sarasquete, M. Eugenia|||0000-0001-7335-3657
  • González, Marcos
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Balanzategui, Ana|||0000-0003-0660-8183
  • Prieto-Conde, Isabel|||0000-0002-2510-8355
  • García-Álvarez, María|||0000-0001-8864-1168
  • Puig, Noemí|||0000-0001-7535-3861
  • González-Calle, Verónica|||0000-0002-5493-6707
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Cuenca, Isabel
  • Barrio, Santiago
  • Escalante, Fernando|||0000-0003-4501-9066
  • Gutierrez, Norma|||0000-0001-5834-9510
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernández, Miguel T.
  • Sureda, Anna|||0000-0002-1238-6970
  • Oriol, Albert|||0000-0001-6804-2221
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Lahuerta, J. J|||0000-0002-3393-9570
  • San Miguel, Jesus F.
  • Mateos, M. V|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361-0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137-0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

  • Medina, Alejandro|||0000-0001-5609-2969
  • Puig, Noemí|||0000-0001-7535-3861
  • Flores-Montero, Juan|||0000-0002-1119-4387
  • Jimenez, Cristina
  • Sarasquete, M. Eugenia|||0000-0001-7335-3657
  • García-Álvarez, María|||0000-0001-8864-1168
  • Prieto-Conde, Isabel|||0000-0002-2510-8355
  • Chillon, Carmen
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Gutierrez, Norma C.
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosinol, Laura
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernandez, Miguel T.
  • Gonzalez-Calle, Verónica
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Orfao, Alberto|||0000-0002-0007-7230
  • González, Marcos
  • García-Sanz, Ramón|||0000-0003-4120-2787
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09-0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06-0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

  • Puig, Noemí|||0000-0001-7535-3861
  • Contreras, María Teresa|||0000-0002-2264-7791
  • Agulló, Cristina
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Oriol, Albert|||0000-0001-6804-2221
  • Blanchard, María Jesús
  • Ríos-Tamayo, Rafael|||0000-0001-8193-1402
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Iñigo Rodríguez, María Belén
  • Sureda, Anna|||0000-0002-1238-6970
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • de la Rubia, Javier|||0000-0002-8354-768X
  • González-Calle, Verónica|||0000-0002-5493-6707
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Cabañas Perianes, Valentín|||0000-0002-6248-2549
  • Palomera, Luis|||0000-0003-0359-7191
  • Moraleda, José María|||0000-0001-9080-1466
  • Bargay, Joan|||0000-0002-6739-3916
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n 5 223), and after induction (n 5 183), autologous stem cell transplantation (n 5 173), and consolidation (n 5 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in.80% of cases, being most discordances due to EXENT&FLC-MS but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P 5.0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

  • Medina, Alejandro
  • Jimenez, Cristina
  • Sarasquete, Maria Eugenia
  • González, Marcos
  • Chillón, M. Carmen
  • Balanzategui, Ana
  • Gironella Mesa, Mercedes
Investigació genètica; Mieloma, Investigación genética; Mieloma, Genetics research; Myeloma, Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program. The authors wish to thank José Pérez, Alicia Antón, Montserrat Hernández-Ruano, Estrella Arnés, Rebeca Maldonado, Mercedes Jiménez, Alejandra Martín, Isabel Sánchez, Rocío Corral and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, as well as the Spanish Multiple Myeloma “GEM-PETHEMA” group for providing clinical data. The authors are also very grateful to the patients who participated in this study.